Payment overview · 2025
General Payments
$2,683.08
123 reported records · 16 companies
Healthcare provider profile · identity verified
Robert Alan Schuster, MD
Allopathic & Osteopathic Physicians|General Practice · DADEVILLE, AL · NPI 1871525931
Verified facts
What the public records show
CMS Open Payments records show Robert Alan Schuster, MD received $2,683.08 in general payments during 2025 across 123 reported records.
Neurocrine BioSciences, Inc. accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aristada, Caplyta, Farxiga, Ingrezza, Invega Sustenna, Invega Trinza, Lybalvi, Ozempic, Rexulti, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Viberzi by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARISTADA as an associated drug or biological on 76041 records involving 17486 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Aristada by this doctor in 2024.
Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Lybalvi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 472 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Trelegy Ellipta by this doctor in 2024.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Caplyta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA TRINZA as an associated drug or biological on 8191 records involving 2146 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Invega Trinza by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xarelto by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ingrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 27924 records involving 10497 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Abilify Maintena by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Rexulti by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $609.02 | 22.7% | 20 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $483.85 | 18.0% | 24 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $385.90 | 14.4% | 17 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $234.22 | 8.7% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $215.74 | 8.0% | 12 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $161.70 | 6.0% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $138.63 | 5.2% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $135.91 | 5.1% | 10 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $74.57 | 2.8% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $57.17 | 2.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $50.39 | 1.9% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $42.53 | 1.6% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $39.60 | 1.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.42 | 0.8% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.36 | 0.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.07 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,683.08 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $609.02 | 20 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $483.85 | 24 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $402.28 | 23 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $385.90 | 17 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $235.45 | 13 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $234.22 | 11 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $161.70 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $135.91 | 10 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $116.04 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $105.69 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $78.32 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.32 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $74.57 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.17 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $50.39 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $42.53 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Otsuka America Pharmaceutical, Inc. | $19.89 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ARISTADA aristada |
2025 | Aristada | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CAPLYTA caplyta |
2025 | Caplyta | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 207 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INVEGA SUSTENNA invega sustenna |
2025 | Invega Sustenna | 2024 | 81 | exact normalized | Medicare Part D |
| INVEGA TRINZA invega trinza |
2025 | Invega Trinza | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYBALVI lybalvi |
2025 | Lybalvi | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 95 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 124 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | ARISTADA open payments reported associated product |
CMS Open Payments — General Payments 76041 supporting records · 17486 recipient NPIs · example record 1222428566 |
Aristada · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Alkermes, Inc. Exact reporting entity; no affiliate inference |
2025 | LYBALVI open payments reported associated product |
CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566 |
Lybalvi · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
207 | 34 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
38 | 11 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
472 | 42 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
124 | 42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference |
2025 | CAPLYTA open payments reported associated product |
CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | Caplyta open payments reported associated product |
CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314 |
Caplyta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA TRINZA open payments reported associated product |
CMS Open Payments — General Payments 8191 supporting records · 2146 recipient NPIs · example record 1174223262 |
Invega Trinza · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 27924 supporting records · 10497 recipient NPIs · example record 1227267721 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
77 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1602 | 228 |
| Amlodipine Besylate | Amlodipine Besylate | 1306 | 212 |
| Losartan Potassium | Losartan Potassium | 1193 | 170 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1149 | 205 |
| Potassium Chloride | Potassium Chloride | 1006 | 141 |
| Gabapentin | Gabapentin | 799 | 171 |
| Levothyroxine Sodium | Levothyroxine Sodium | 749 | 130 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 740 | 130 |
| Sertraline Hcl | Sertraline Hcl | 658 | 46 |
| Carvedilol | Carvedilol | 641 | 89 |
| Memantine Hcl | Memantine Hcl | 612 | 44 |
| Trazodone Hcl | Trazodone Hcl | 507 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 500 | 37 |
| Divalproex Sodium | Divalproex Sodium | 475 | 26 |
| Eliquis | Apixaban | 472 | 42 |
| Metformin Hcl | Metformin Hcl | 470 | 108 |
| Montelukast Sodium | Montelukast Sodium | 442 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 436 | 60 |
| Mirtazapine | Mirtazapine | 421 | 64 |
| Omeprazole | Omeprazole | 410 | 65 |
| Escitalopram Oxalate | Escitalopram Oxalate | 409 | 69 |
| Donepezil Hcl | Donepezil Hcl | 408 | 43 |
| Famotidine | Famotidine | 378 | 37 |
| Benztropine Mesylate | Benztropine Mesylate | 353 | 52 |
| Meloxicam | Meloxicam | 345 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 342 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 333 | 103 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 325 | 92 |
| Furosemide | Furosemide | 302 | 59 |
| Lisinopril | Lisinopril | 300 | 49 |
| Tramadol Hcl | Tramadol Hcl | 281 | 73 |
| Clonazepam | Clonazepam | 266 | 59 |
| Risperidone | Risperidone | 264 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 258 | 80 |
| Allopurinol | Allopurinol | 255 | 44 |
| Methocarbamol | Methocarbamol | 248 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 241 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 228 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 221 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 220 | 102 |
| Aripiprazole | Aripiprazole | 217 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 34 |
| Farxiga | Dapagliflozin Propanediol | 207 | 34 |
| Olanzapine | Olanzapine | 186 | 16 |
| Ezetimibe | Ezetimibe | 183 | 51 |
| Prednisone | Prednisone | 183 | 64 |
| Ropinirole Hcl | Ropinirole Hcl | 179 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 167 | 114 |
| Amitriptyline Hcl | Amitriptyline Hcl | 164 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 163 | 25 |
| Simvastatin | Simvastatin | 163 | 53 |
| Metformin Hcl Er | Metformin Hcl | 160 | 24 |
| Bupropion Xl | Bupropion Hcl | 158 | 52 |
| Pregabalin | Pregabalin | 157 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 150 | 66 |
| Levetiracetam | Levetiracetam | 149 | suppressed |
| Jardiance | Empagliflozin | 146 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 146 | 27 |
| Mounjaro | Tirzepatide | 144 | 21 |
| Buspirone Hcl | Buspirone Hcl | 142 | 26 |
| Sucralfate | Sucralfate | 142 | 41 |
| Propranolol Hcl | Propranolol Hcl | 141 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 140 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 133 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 131 | 23 |
| Lorazepam | Lorazepam | 125 | 31 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 124 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 120 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 116 | 23 |
| Labetalol Hcl | Labetalol Hcl | 115 | suppressed |
| Colchicine | Colchicine | 112 | 50 |
| Glimepiride | Glimepiride | 109 | 18 |
| Meclizine Hcl | Meclizine Hcl | 109 | 20 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 16 |
| Ozempic | Semaglutide | 103 | 29 |
| Torsemide | Torsemide | 103 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 101 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 101 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 99 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 99 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 98 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 97 | 21 |
| Azithromycin | Azithromycin | 96 | 72 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 96 | 35 |
| Rexulti | Brexpiprazole | 95 | 23 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 93 | suppressed |
| Digoxin | Digoxin | 92 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 91 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 88 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 86 | 33 |
| Benazepril Hcl | Benazepril Hcl | 84 | 11 |
| Spironolactone | Spironolactone | 84 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 82 | 13 |
| Invega Sustenna | Paliperidone Palmitate | 81 | 13 |
| Fluconazole | Fluconazole | 80 | 41 |
| Linzess | Linaclotide | 80 | 26 |
| Abilify Maintena | Aripiprazole | 77 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 66 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 74 | 14 |
| Naproxen | Naproxen | 74 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 72 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 17 |
| Topiramate | Topiramate | 71 | 25 |
| Bumetanide | Bumetanide | 70 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 70 | 18 |
| Fenofibrate | Fenofibrate,micronized | 69 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 69 | 28 |
| Ibuprofen | Ibuprofen | 65 | suppressed |
| Lamotrigine | Lamotrigine | 63 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 63 | suppressed |
| Dutasteride | Dutasteride | 62 | 20 |
| Ramipril | Ramipril | 62 | suppressed |
| Celecoxib | Celecoxib | 60 | 22 |
| Myrbetriq | Mirabegron | 60 | suppressed |
| Haloperidol | Haloperidol | 56 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 55 | suppressed |
| Brilinta | Ticagrelor | 54 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 53 | 14 |
| Terazosin Hcl | Terazosin Hcl | 53 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 52 | suppressed |
| Cefdinir | Cefdinir | 52 | 49 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 50 | suppressed |
| Silodosin | Silodosin | 50 | suppressed |
| Amantadine | Amantadine Hcl | 49 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 49 | 16 |
| Ondansetron Odt | Ondansetron | 49 | 13 |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 49 | suppressed |
| Alprazolam | Alprazolam | 48 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 11 |
| Clozapine | Clozapine | 47 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 47 | 14 |
| Liothyronine Sodium | Liothyronine Sodium | 46 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 46 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 45 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 45 | 12 |
| Baclofen | Baclofen | 44 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 33 |
| Lansoprazole | Lansoprazole | 42 | suppressed |
| Atenolol | Atenolol | 40 | 12 |
| Haloperidol Decanoate | Haloperidol Decanoate | 40 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 39 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 39 | suppressed |
| Lybalvi | Olanzapine/Samidorphan Malate | 38 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 37 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 35 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 35 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 34 | suppressed |
| Rybelsus | Semaglutide | 34 | 11 |
| Azelastine Hcl | Azelastine Hcl | 33 | 14 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 26 |
| Nystatin | Nystatin | 32 | 24 |
| Lactulose | Lactulose | 31 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 29 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 27 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 26 | suppressed |
| Austedo | Deutetrabenazine | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Repatha Sureclick | Evolocumab | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 22 |
| Mupirocin | Mupirocin | 24 | 16 |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 16 |
| Finasteride | Finasteride | 23 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 19 | suppressed |
| Ingrezza | Valbenazine Tosylate | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 16 |
| Verapamil Er | Verapamil Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Caplyta | Lumateperone Tosylate | 18 | suppressed |
| Cephalexin | Cephalexin | 18 | 15 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 18 |
| Testosterone | Testosterone | 18 | suppressed |
| Aristada | Aripiprazole Lauroxil | 17 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 17 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Diazepam | Diazepam | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 12 |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Invega Trinza | Paliperidone Palmitate | 13 | suppressed |
| Klor-Con 10 | Potassium Chloride | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Trulance | Plecanatide | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Cozaar | Losartan Potassium | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 12 | 12 |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 12 | suppressed |
| Norvasc | Amlodipine Besylate | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Viberzi | Eluxadoline | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,683.08 · 123 records | Neurocrine BioSciences, Inc. | ABILIFY ASIMTUFII, AIRSUPRA, ARISTADA, AUSTEDO XR, BREZTRI, CAPLYTA, COBENFY, FANAPT, FARXIGA, IBSRELA, INGREZZA, INVEGA SUSTENNA, INVEGA TRINZA, Kerendia, LYBALVI, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA, VRAYLAR | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aristada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error